sildenafil / Generic mfg. - LARVOL DELTA

Preventive Effects of trans-4-Methoxy-β-nitrostyrene on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. (PubMed, Fundam Clin Pharmacol) - "Taken together, the present study provided the first evidence that T4MN prevents the development of MCT-induced HAP in rats. Further mechanistic studies of these protective effects of T4MN are warranted."

Journal • Preclinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • IL6 • NOS3

Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study. (PubMed, J Gynecol Obstet Hum Reprod) - "Overall, biomarkers of oxidative stress improved in the metformin-only, melatonin, and sildenafil groups, suggesting that these drugs may have protective effects in PCOS patients. However, further studies are needed to determine their effectiveness."

Journal • Metabolic Disorders • Polycystic Ovary Syndrome

THERAPEUTIC POTENTIAL OF SILDENAFIL AND 5HT2B RECEPTOR ANTAGONIST IN PERITONEAL FIBROSIS THROUGH MODULATION OF FIBROBLAST METABOLISM AND DIFFERENTIATION (ISN-WCN 2026) - "Figure 1Download: Download high-res image (222KB)Download: Download full-size imageConclusion Sildenafil attenuates peritoneal fibrosis by inhibiting fibroblast activation through metabolic reprogramming and immune modulation. These findings highlight the therapeutic potential of sildenafil in preventing PF and preserving peritoneal membrane function in PD patients."

Fibrosis • Immune Modulation • Immunology • Inflammation • FN1 • IL10 • LDHA • SLC2A1 • TGFB1

Guipi Decoction Attenuates Fibrosis and Oxidative Stress to Ameliorate Diabetic Erectile Dysfunction in Rats via the RhoA/ROCK Signaling Pathway. (PubMed, Endocr Metab Immune Disord Drug Targets) - "Guipi Decoction effectively improves erectile function and ameliorates penile histopathological lesions in DMED rats, suggesting its potential as a therapeutic agent for DMED through modulation of the RhoA/ROCK signaling pathway."

Journal • Preclinical • Erectile Dysfunction • Fibrosis • Immunology • CASP3 • RHOA • ROCK1

Pulmonary hypertension in dogs with myxomatous mitral valve disease. (PubMed, J Vet Cardiol) - "Sildenafil and other pulmonary vasodilators have been used with variable clinical benefits in dogs with MMVD and concurrent PH, though evidence remains limited and sometimes conflicting. Prognosis is influenced by both severity of valve disease and degree of pulmonary vascular involvement, underscoring the importance of timely recognition and individualized management. Understanding the interplay between MMVD and PH is critical for optimizing outcomes, guiding treatment decisions, and informing future clinical research in veterinary cardiology."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Senescence as a Central Node in Alzheimer's Disease: Molecular Triggers, Cellular Effectors, and RNA-Based Interventions. (PubMed, Neurochem Res) - "Approaches including VEGFR-1 and SIRT5 interference, senolytics or senomorphs drugs, NLRP3 antagonist, PAI-1 inhibitors and small vessels inhibitors (including aspirin, curcumin derivatives and sildenafil) have been suggested to promisingly mitigate brain injury. RNA based therapy (miRNAs- and lncRNAs-targeted) and exosomal derived biomarkers are also an optimistic approach. A clearer understanding of how senescence is implicated in AD would have implications regarding the design and application of novel treatments aimed at delaying disease onset, slowing down progression or preserving brain function."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Vascular Neurology • FLT1 • NLRP3 • SIRT5

Pulmonary Hypertension Hyper-Responder to Valve-in-Valve TMVR Under Conscious Sedation. (PubMed, JACC Case Rep) - "ICE-guided TMVR under conscious sedation (in combination with pulmonary vasodilators) can be safe in select severe PH patients, achieving significantly lower pulmonary pressures with meaningful symptom improvement."

Journal • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Role of sildenafil in neuronal plasticity after neonatal hypoxic-ischemic encephalopathy: Linking morphological recovery with proteomics profiling (PAS 2026) - No abstract available

CNS Disorders

Inhaled Sildenafil and Preterm Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Prevention of Murine Bronchopulmonary Dysplasia (PAS 2026) - No abstract available

Preclinical • Prematurity • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Direct Pulmonary Delivery of Sildenafil Enhances Therapeutic Outcomes in Experimental Bronchopulmonary dysplasia (PAS 2026) - No abstract available

Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Beyond iNO and sildenafil: treatment of severe and chronic pulmonary hypertension (PAS 2026) - No abstract available

Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

REFRACTORY DIGITAL ULCERS AND CHRONIC OSTEOMYELITIS COMPLICATING DIFFUSE SYSTEMIC SCLEROSIS: A REAL-LIFE CASE (SSWC 2026) - "Digital ulcers were refractory to nifedipine 60 mg/day, prompting escalation to alprostadil in 2013 and iloprost in 2016, both initially effective...Sildenafil (up to 150 mg/day, 2024–2025) proved ineffective. Bosentan, initiated in January 2025, was discontinued after re-hospitalization in August 2025 for multiple ulcers and chronic osteomyelitis of the right fifth digit...Osteomyelitis developed in the right second digit in 2019, requiring multiple antibiotic courses (flucloxacillin, amoxicillin–clavula- nate, clindamycin, trimethoprim–sulfamethoxazole) following Staphylococcus aureus isolation, with relapse in 2020 managed with ciprofloxacin...Mycophenolate mofetil (2017–2019) was used for progressive skin fibrosis and NSIP but discontinued due to recurrent osteomyeli- tis. Nintedanib (2021–2024) was initiated for progressive pulmonary fibrosis but withdrawn due to severe diarrhea and weight loss... This case illustrates the complex therapeutic challenges in SSc..."

Clinical • Cardiovascular • Fibrosis • Hepatology • Hypotension • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Musculoskeletal Diseases • Orthopedics • Pneumonia • Primary Biliary Cholangitis • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Venous Ulcer

BUSULFAN ASSOCIATED PULMONARY TOXICITY AND INFECTIOUS COMPLICATIONS FOLLOWING AUTOLOGOUS SCT IN A 3-YEAR-OLD CHILD WITH NEUROBLASTOMA (EBMT 2026) - "Background: High-dose busulfan/melphalan (Bu/Mel) remains a standard conditioning regimen for autologous stem cell transplantation in high-risk neuroblastoma but is associated with significant organ toxicity, particularly hepatic and pulmonary injury...A treatment with Defibrotide, Ganciclovir and Azithromycin was initiated...We started a treatment with Sildenafil, Macitentan, Epoprostenol in addition to Methylprednisolone pulse therapy and antifibrotic treatment with Nintedanib, Hydroxychloroquin and Azithromycin... This case illustrates the complex interplay between infectious complications, post-transplant inflammation and busulfan-induced pulmonary toxicity in a young neuroblastoma patient undergoing Bu/Mel conditioning and autologous SCT. Consideration of busulfan toxicities, especially when presenting with nonspecific early symptoms is important even when alternative explanations such as severe infection may appear equally plausible after autologous SCT. Early..."

Clinical • Acute Respiratory Distress Syndrome • Cardiovascular • Cystic Fibrosis • Cytomegalovirus Infection • Gastroenterology • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Neuroblastoma • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • Solid Tumor

Outcome of Pediatric Pulmonary Hypertension Patients Requiring ECMO (SCCM 2026) - "100% (31/31) of patients received at least one PAH therapy prior to and during ECMO [31/31 (100%) inhaled nitric oxide or inhaled epoprostenol; 26/31 (84%) sildenafil, tadalafil or riociugat; 18/31 (58%) macitentan, ambrisentan or bosentan; 8/31(26%) selexipag; 10/31(32%) treprostinil. Pediatric PAH is a complex disease due to varied etiologies often requiring multiple medications to effectively manage. Certain subpopulations such as those with single ventricle CHD have higher mortality especially when requiring ECMO. Further study is necessary to determine if earlier identification and management of PAH patients prior to ECMO can improve survival and decrease need for mechanical circulatory support in this high-risk population."

Clinical • Cardiovascular • Heart Failure • Hematological Disorders • Infectious Disease • Pediatrics • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Tranexamic Acid-Associated Cardiovascular Collapse in an Infant Undergoing Cranial Vault Surgery (SCCM 2026) - "We present a case of prolonged cardiovascular collapse following TXA administration in a high-risk infant with complex medical comorbidities.Description: An 8-month-old ex-22w3d female infant with severe bronchopulmonary dysplasia, pulmonary hypertension on sildenafil, adrenal insufficiency, and bicoronal craniosynostosis was admitted to the PICU pre-operatively for planned cranial vault reconstruction...After immediate transfer to the PICU, she experienced persistent cardiovascular collapse requiring code-dose epinephrine, brief CPR, and several hours of inotropic support...As TXA use expands in pediatric surgical protocols, clinicians should be vigilant when using it in high-risk infants. Multidisciplinary planning, cautious dosing, and preparedness for hemodynamic instability are essential."

Surgery • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Depression • Endocrine Disorders • Hematological Disorders • Hypotension • Infectious Disease • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock

Comparative Effectiveness of Endothelin Receptor Antagonists and PDE-5 Inhibitors in PAH (SCCM 2026) - "Adults carrying an ICD-10 code for PAH (I27.0) who started either ERA monotherapy (bosentan, ambrisentan, macitentan) or PDE5I monotherapy (sildenafil, tadalafil) with no prior prostacyclin or combination therapy were eligible. n this large multicentre, propensity-matched analysis of treatment-naive PAH, ERAs and PDE5Is produced indistinguishable 12-month survival, cardiovascular outcomes, and adverse-event rates. These findings support current guidelines that either class is an acceptable first-line option; choice may therefore be guided by individual comorbidity profiles, side-effect tolerance, and cost rather than expectations of differential efficacy."

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Pulmonary Arterial Hypertension • Respiratory Diseases

Pulmonary Hypertension Associated With Vitamin C Deficiency Is Rapidly Reversible. (PubMed, Pediatrics) - "Importantly, 1 child receiving sildenafil alone showed no therapeutic response until vitamin C was added, indicating that improvement requires correction of the underlying deficiency rather than pulmonary vasodilation alone. This case series demonstrates rapid reversibility of vitamin C deficiency-associated PH and emphasizes the importance of considering this diagnosis in children with restricted diets and unexplained PH."

Journal • Autism Spectrum Disorder • Cardiovascular • Heart Failure • Hypertension • Musculoskeletal Diseases • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A PROACTIVE APPROACH TO FONTAN-ASSOCIATED LIVER DISEASE: THE CRITICAL ROLE OF INVASIVE HEMODYNAMIC ASSESSMENT (ACC 2026) - "He was clinically asymptomatic while on warfarin and carvedilol...A final central venous pressure of 16 mmHg led to the initiation of sildenafil to further optimize hepatic decongestion... This case underscores the limitations of non-invasive imaging and highlights the critical role of clinical suspicion in guiding the invasive investigation in Fontan patients. Our findings suggest that correcting a pressure gradient combined with pharmacological optimization using phosphodiesterase-5 inhibitors represents a crucial proactive strategy in the management of FALD and its benefits outweigh the risks when compared to a conservative approach."

Cardiovascular • Fibrosis • Hepatology • Immunology • Liver Failure • Portal Hypertension

VOLATILE ORGANIC COMPOUND EXPOSURE, SCLERODERMA-SPECTRUM AUTOIMMUNITY, AND PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "He was started on sildenafil, inhaled treprostinil, diuretics, and rate control. In unexplained PAH with autoimmune serologies, environmental history can expedite diagnosis of SSc-spectrum PAH and allow early targeted therapy."

Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Respiratory Diseases • Scleroderma • Systemic Sclerosis

MANAGING PREGNANCY IN A PATIENT WITH UNREPAIRED TRUNCUS ARTERIOSUS AND PULMONARY HYPERTENSION (ACC 2026) - "She was on sildenafil, bosentan, and full-dose enoxaparin for thromboembolism prevention...Decision-Making: As pregnancy continued, sildenafil was continued, bosentan stopped, and oxygen, iloprost, and aspirin added... Pregnancy is contraindicated in pulmonary arterial hypertension due to Truncus Arteriosus. The European and American Society of Cardiology advise termination of pregnancy during the first trimester. If continued, management should focus on O₂ >90% and preventing thrombotic events."

Clinical • Cardiovascular • Heart Failure • Hematological Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

COMPARATIVE EFFECTIVENESS OF RIOCIGUAT VERSUS SILDENAFIL IN EXERCISE INDUCED PULMONARY HYPERTENSION: A SINGLE-CENTER RETROSPECTIVE STUDY (ACC 2026) - "Riociguat improved functional status in EiPH compared to Sildenafil. Larger prospective studies are needed to validate efficacy."

HEOR • Retrospective data • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

CARDIOGENIC SHOCK DUE TO GROUP 1 PULMONARY HYPERTENSION IN A PATIENT ON BORTEZOMIB AND WITH SUBCLINICAL SJOGREN SYNDROME (ACC 2026) - "Decision-Making: Epoprostenol was started, pressors weaned, and eventually transitioned to treprostinil and sildenafil. Group 1 PAH leading to cardiogenic shock can be induced by bortezomib with underlying connective tissue disease and may be reversible upon stopping bortezomib with PH therapy."

Clinical • Cardiovascular • Hematological Malignancies • Hypertension • Immunology • Multiple Myeloma • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Sjogren's Syndrome

THE BREAKING POINT: RIGHT HEART FAILURE IN SEVERE SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "The initiation of epoprostenol (a gold standard parenteral prostacyclin), along with sildenafil and aggressive inotropic support (milrinone) and pulmonary vasodilation (iNO), stabilized the patient. Severe SSc-associated PAH presenting with cardiogenic shock requires rapid, multi-modal intervention with a parenteral prostacyclin and hemodynamic monitoring. These presentations with extreme PAH severity and critical CI necessitate urgent advanced therapy evaluation, reflecting the current shift toward aggressive, goal-directed treatment for highest-risk PAH populations."

Acute Respiratory Distress Syndrome • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology • Immunology • Pulmonary Arterial Hypertension • Respiratory Diseases • Scleroderma • Systemic Sclerosis

FROM B-CELL LEUKEMIA TREATMENT TO BREATHLESS: A CASE OF PONATINIB-INDUCED PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "Case: A 60-year-old female who received dasatinib and ponatinib before allogeneic stem cell transplant (SCT) for Ph-positive B-cell ALL presented with dyspnea one week after re-initiation of ponatinib...She was started on sildenafil and furosemide with mild clinical improvement and discharged with close follow up... PAH should be considered in the differential in patients on ponatinib therapy with new onset dyspnea."

Clinical • Hematological Malignancies • Leukemia • Pulmonary Arterial Hypertension • Pulmonary Embolism • Respiratory Diseases

THE ELABORATE SCHEME OF EISENMENGER SYNDROME (ACC 2026) - "She was managed with airway clearance, chest physiotherapy, and started on sildenafil and midodrine. With increasing survival of CHD patients into adulthood, early recognition and treatment of PAH and its complication remain essential."

Atrial Fibrillation • Cardiovascular • Heart Failure • Metabolic Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases